Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Duncan B. McLaren et al.|The Lancet Oncology|2019Cited by 643
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquı́n Mateo, Johann S. de Bono, George Seed et al.|Journal of Clinical Investigation|2019Cited by 303
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable OutcomesMatthew Clarke|Cancer Discovery|2020Cited by 276
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancerDaniel Nava Rodrigues, Charles G. Drake, Pasquale Rescigno et al.|Journal of Clinical Investigation|2018Cited by 209